Desperate Choice: NZ Woman’s $40K/Year Treatment Leaves Family with Heartbreaking Dilemma
A 42-year-old New Zealand woman with severe, treatment-resistant neuropathic pain (chronic nerve pain) found temporary relief in a newly approved NMDA receptor antagonist—a $40,000/year gene therapy (brand name: Neuradex)—after failing ... Read More